CoQ10 treatment of patients with CHF and effects of BNP level

Medvedev, O.; Tokareva, O.; Gorodetskaya, E.; Kalenikova, E.; Sizova, Z.

Авторы: Oleg Medvedev, Tokareva OG, Gorodetskaya EA, Kalenikova EI, Sizova ZM
Журнал: European Journal of Heart Failure
Том: 18
Номер: Suppl. S1
Год издания: 2016
Издательство: Elsevier BV
Местоположение издательства: Netherlands
Первая страница: 107
Последняя страница: 107
Аннотация: Background: CoQ10 is a powerful antioxidant and is one of recommended for CHF treatment. Decreased level of myocardial CoQ10 is correlated with the severity of symptoms and the degree of left ventricular dysfunction. Brain natriuretic peptide (BNP) is a peptide, which has recently been used in the differential diagnosis and follow-up of patients with heart failure. It is well known that the severity of the disease also correlates with the plasma BNP levels. Purpose: To evaluate the effects of long-term coenzyme Q10 treatment as part of standard therapy in patients with NYHA class II-III chronic heart failure on plasma BNP levels, left ventricular ejection fraction, and the 6-minute walk test. Materials and Methods: 78 patients with NYHA class II-III chronic heart failure aged from 40 to 70 years with EF less than 45% were randomized in clinical trial. During the study period (24 weeks) participants received solubilized oral form of CoQ10 (90 mg/d) or placebo in addition to standard medical therapy. Left ventricular ejection fraction, 6-minute walk test, plasma brain natriuretic peptide (BNP) (fluorescent analyser with test strips) and CoQ10 levels (HPLC with electrochemical detection) were measured in all patients prior to and after six months treatment. Results: In 37 patients from 78 the baseline level of BNP was below 100 pg/ml. 6 months administration of CoQ10 did nor change BNP level, but in placebo group BNP level increased by 176% ((=0,0092). In group of 41 patients baseline level of BNP was above 100 pg/ml level. In this group administration of CoQ10 was followed by the decrease in BNP level by 6.8% (p=0.02) whereas in placebo group BNP level did not change. Conclusion: 6 months administration of coenzyme Q10 prevents progression of congestive heart failure in patients with reduced contractility and baseline plasma BNP levels within normal ranges (less than 100 pg/ml) and leads to a significant reduction of BNP levels in patients with initial BNP levels higher than 100 pg/ml, increase in left ventricular ejection fraction and improvement in exercise tolerance.
Добавил в систему: Городецкая Евгения Ароновна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

CoQ10 treatment of patients with CHF and effects of BNP levelстатья Тезисы